NASDAQ:SPRO - Spero Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spero Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.00 +0.24 (+3.09 %) (As of 03/30/2020 04:00 PM ET) Add Compare Today's Range$7.76Now: $8.00▼$8.0250-Day Range$5.27MA: $8.48▼$10.4152-Week Range$5.25Now: $8.00▼$14.48Volume75,185 shsAverage Volume98,306 shsMarket Capitalization$162.62 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO Previous Symbol CUSIPN/A CIK1701108 Webhttp://www.sperotherapeutics.com/ Phone857-242-1600Debt Debt-to-Equity Ratio0.06 Current Ratio3.58 Quick Ratio3.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.15 million Price / Sales8.96 Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book2.05Profitability EPS (Most Recent Fiscal Year)($3.35) Net Income$-60,920,000.00 Net Margins-336.96% Return on Equity-62.62% Return on Assets-52.51%Miscellaneous Employees41 Outstanding Shares20,328,000Market Cap$162.62 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive SPRO News and Ratings via Email Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SPRO Rates by TradingView Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions How has Spero Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SPRO shares have increased by 3.2% and is now trading at $8.00. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Spero Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spero Therapeutics. When is Spero Therapeutics' next earnings date? Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Spero Therapeutics. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics Inc (NASDAQ:SPRO) issued its earnings results on Monday, March, 16th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.05) by $0.27. The company earned $3.63 million during the quarter, compared to the consensus estimate of $3.54 million. Spero Therapeutics had a negative return on equity of 62.62% and a negative net margin of 336.96%. View Spero Therapeutics' earnings history. What price target have analysts set for SPRO? 5 equities research analysts have issued twelve-month price objectives for Spero Therapeutics' stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Spero Therapeutics' share price to reach $25.75 in the next year. This suggests a possible upside of 221.9% from the stock's current price. View analysts' price targets for Spero Therapeutics. What are Wall Street analysts saying about Spero Therapeutics stock? Here are some recent quotes from research analysts about Spero Therapeutics stock: 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (2/28/2020) 2. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value SPR994 (oral carbapenem) – cUTI 62% $22.87 $36.88 Shares outstanding 18,656 S/O as of SPR741 (IV potentiator) – MDR Gram (-) $3.22 $3.22 Current share price $9.23 Discount rate 14.5% SPR720 (oral treatment) – NTM $1.34 $1.34." (8/12/2019) 3. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for 2019+. Anticipated 2019 events include pharmacokinetic data from a lead-in cohort of 70 patients in 2H19 for SPR994 in the cUTI patient population, Phase 1 data for 1 data for SPR720." (5/9/2019) Has Spero Therapeutics been receiving favorable news coverage? Press coverage about SPRO stock has been trending negative on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Spero Therapeutics earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutSpero Therapeutics. Are investors shorting Spero Therapeutics? Spero Therapeutics saw a decrease in short interest in February. As of February 28th, there was short interest totaling 439,800 shares, a decrease of 42.5% from the February 13th total of 764,900 shares. Based on an average trading volume of 86,900 shares, the short-interest ratio is currently 5.1 days. Currently, 3.1% of the shares of the stock are sold short. View Spero Therapeutics' Current Options Chain. Who are some of Spero Therapeutics' key competitors? Some companies that are related to Spero Therapeutics include Eagle Pharmaceuticals (EGRX), Rhythm Pharmaceuticals (RYTM), Arcus Biosciences (RCUS), Frequency Therapeutics (FREQ), Radius Health (RDUS), Omeros (OMER), ImmunoGen (IMGN), Retrophin (RTRX), Cara Therapeutics (CARA), Nabriva Therapeutics (NBRV), Portola Pharmaceuticals (PTLA), Collegium Pharmaceutical (COLL), ZIOPHARM Oncology (ZIOP), Clovis Oncology (CLVS) and Vanda Pharmaceuticals (VNDA). What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Crispr Therapeutics (CRSP), Catalyst Pharmaceuticals (CPRX), Rigel Pharmaceuticals (RIGL), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amicus Therapeutics (FOLD), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX) and NovaBay Pharmaceuticals (NBY). Who are Spero Therapeutics' key executives? Spero Therapeutics' management team includes the following people: Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)Mr. Joel D. Sendek, CFO, Treasurer & Sec. (Age 52)Ms. Cristina Larkin, Chief Operating Officer (Age 49)Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)Ms. Sharon Klahre, Director of Investor Relations When did Spero Therapeutics IPO? (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." Who are Spero Therapeutics' major shareholders? Spero Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (4.42%), Renaissance Technologies LLC (1.77%), State Street Corp (1.09%), Geode Capital Management LLC (0.62%), FMR LLC (0.52%) and Oxford Asset Management LLP (0.31%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View institutional ownership trends for Spero Therapeutics. Which institutional investors are selling Spero Therapeutics stock? SPRO stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, FMR LLC, Oxford Asset Management LLP, Panagora Asset Management Inc., and Nuveen Asset Management LLC. View insider buying and selling activity for Spero Therapeutics. Which institutional investors are buying Spero Therapeutics stock? SPRO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Stifel Financial Corp, Janney Montgomery Scott LLC, State Street Corp, Russell Investments Group Ltd., and Barclays PLC. View insider buying and selling activity for Spero Therapeutics. How do I buy shares of Spero Therapeutics? Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $8.00. How big of a company is Spero Therapeutics? Spero Therapeutics has a market capitalization of $162.62 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 41 workers across the globe. View additional information about Spero Therapeutics. What is Spero Therapeutics' official website? The official website for Spero Therapeutics is http://www.sperotherapeutics.com/. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected] MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 154 (Vote Outperform)Underperform Votes: 139 (Vote Underperform)Total Votes: 293MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/30/2020 by MarketBeat.com StaffFeatured Article: How Do Front-End Loads Impact an Investment?
